Devita, Hellman, and Rosenberg's Cancer

LWBK1006-20 LWW-Govindan-Review December 12, 2011 19:4

Chapter 20•Cancer of the Gastrointestinal Tract 273

Question 20.5.17.All of the following statements regarding systemic therapy for metastatic

colorectal cancer is true, EXCEPT:

A. Treatment with FOLFOX and panitumumab results in improved

progression-free survival compared to FOLFOX alone in patients

with KRAS wild type.

B. Both FOLFOX and FOLFIRI have similar treatment efficacy in the

first-line setting.

C. Treatment with combination chemotherapy regimens leads to supe-

rior outcomes than single-agent chemotherapy in the first-line setting.

D. Arterial thrombotic events and bowel perforation are serious risk

factors associated with bevacizumab.